The Anticonvulsant Screening Program of the National Institute of Neurological Disorders and Stroke, NIH: History and Contributions to Clinical Care in the Twentieth Century and Beyond
Autor: | Roger J. Porter, Harvey J. Kupferberg |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Neurology Drug Evaluation Preclinical Biochemistry 03 medical and health sciences Cellular and Molecular Neuroscience Epilepsy 0302 clinical medicine Drug Discovery medicine Animals Humans Epilepsy therapy National Institute of Neurological Disorders and Stroke (U.S.) Clinical care Psychiatry Stroke Clinical Trials as Topic business.industry General Medicine medicine.disease United States 030104 developmental biology Drug development Anticonvulsants business 030217 neurology & neurosurgery |
Zdroj: | Neurochemical Research. 42:1889-1893 |
ISSN: | 1573-6903 0364-3190 |
Popis: | The anticonvulsant screening program (ASP) of the national institute of neurological disorders and stroke (NINDS), National Institutes of Health has made substantial contributions to the drug armamentarium of the clinical neurologist. This program, originally a part of the overall Drug Development Program of the Epilepsy Branch, has been fortunate to have talented leadership, both at NINDS in Maryland and at the major contract site, the University of Utah-over a remarkable period of more than 40 years. Future discoveries by the ASP (now renamed the Epilepsy Therapy Screening) can be expected to make additional contributions to improving the health of persons with epilepsy. |
Databáze: | OpenAIRE |
Externí odkaz: |